NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.89 Consensus Target Price from Brokerages

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received a consensus rating of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $19.89.

Several equities research analysts have recently issued reports on the stock. Benchmark restated a “buy” rating and issued a $18.00 target price on shares of NeoGenomics in a report on Tuesday, September 24th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a research note on Wednesday. Finally, Stephens restated an “overweight” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Tuesday, July 30th.

Institutional Trading of NeoGenomics

A number of large investors have recently modified their holdings of NEO. Bellevue Group AG bought a new stake in shares of NeoGenomics in the 1st quarter valued at about $14,872,000. Kopp LeRoy C purchased a new position in NeoGenomics during the first quarter valued at approximately $14,062,000. First Light Asset Management LLC lifted its holdings in NeoGenomics by 14.5% during the second quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock worth $52,464,000 after buying an additional 480,396 shares during the period. Jennison Associates LLC boosted its position in NeoGenomics by 77.8% during the 1st quarter. Jennison Associates LLC now owns 1,051,627 shares of the medical research company’s stock valued at $16,532,000 after acquiring an additional 460,071 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in NeoGenomics by 7.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock valued at $46,108,000 after acquiring an additional 217,687 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Trading Up 2.3 %

Shares of NEO stock opened at $15.82 on Tuesday. The company has a market cap of $2.03 billion, a PE ratio of -25.52 and a beta of 1.19. NeoGenomics has a 1 year low of $12.77 and a 1 year high of $21.22. The stock’s 50 day simple moving average is $14.69 and its two-hundred day simple moving average is $14.73. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.04. The company had revenue of $167.80 million for the quarter, compared to analyst estimates of $167.00 million. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. NeoGenomics’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.06) EPS. Research analysts predict that NeoGenomics will post -0.21 earnings per share for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.